Peek behind the paper: real-world evidence for evaluating a novel melanoma treatment

Written by The Evidence Base

In this feature, we take a peek behind the paper with contributing authors Matthew Perez and Jonathan Zager: the COSMUS-I study. The COSMUS-I study was undertaken on the back of significant advances over the last decade in the treatment of melanomas with targeted and immuno-therapies. COSMUS-I aimed to assess the efficacy of talimogene laherparepvec (T-VEC) — a novel melanoma therapy — as a routine clinical practice treatment for metastatic melanoma patients in the USA. In this feature, we peek behind the paper with contributing study authors Matthew Perez and Jonathan Zager — both from the Moffitt Cancer Center (FL, USA)...

To view this content, please register now for access

It's completely free